Skip to main content
. 2023 Dec 16;11(35):8300–8309. doi: 10.12998/wjcc.v11.i35.8300

Table 4.

Prognosis of patients in the two groups

Project
GTG
ITG
χ2
P value
Renal endpoint 14 7
Serious infection 4 2
Serious liver injury 4 2
Serious complication 10 8
Incidence of endpoint events 32% 19% 4.448 0.035
Follow-up time (mo) 10.11 ± 3.09 11.07 ± 2.08 2.000 0.048

GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group.